8/23/2007

The FDA on Wednesday approved the use of Johnson & Johnson's antipsychotic drug Risperdal in children and adolescents with schizophrenia or bipolar disorder. The American Psychiatric Association welcomed the agency's decision, saying it "will encourage federal research agencies to accelerate urgently needed studies of mental disorders in children."

Related Summaries